PORTLAND, OR – MARCH 10, 2026 / PR Newswire / – GTT Group, the global leader in patent-backed strategic transactions, today announced it is exclusively representing the acquisition of Solaana MD, a physician-founded, patent-protected dermocosmetics brand poised for global scale.
Solaana MD offers a turnkey opportunity for a strategic acquirer to dominate a new, untapped category in the $76billion dermocosmetics market. The company has developed and commercialized a first-in-class, high-absorption, topical Vitamin D delivery system that addresses a well-documented, unmet need for millions of consumers.
Solving the Vitamin D Paradox: A $15 Billion Unmet Need
The modern skincare industry has created an unintended public health dilemma. While daily sunscreen use is universally recommended to protect against UV damage and skin cancer, long-term UV avoidance suppresses the skin’s natural ability to synthesize Vitamin D. The skin’s ability to synthesize Vitamin D is essential for immune function, skin barrier integrity, and the management of inflammatory conditions. The result is a malnourishment condition impacting an estimated 40% of U.S. adults that are Vitamin D deficient, and the problem is compounded for the over 30 million Americans living with chronic skin conditions such as eczema and psoriasis.
With oral Vitamin D supplementation, the conventional remedy for Vitamin D deficiency, being unreliable for a substantial portion of the population as well, Solaana MD’s patented formulation resolves the Vitamin D paradox directly. Engineered as a cosmetically elegant, low-viscosity emulsion applied as a base layer beneath sunscreen, or simply as part of daily cosmetic/skincare routine, the product delivers Vitamin D transdermally, bypassing the gastrointestinal system entirely and supporting localized Vitamin D availability at the skin level. The result is a product that is simultaneously a dermocosmetic, a functional wellness product, and a daily skincare essential.
A Strategic Imperative
“Solaana MD is a strategic imperative for any major beauty or pharmaceutical player looking to own the next frontier of science-backed skincare,” said Tyler McKinley, Managing Director of GTT Group. “It’s a high-growth, high-margin, patent-protected business that can be plugged into a global distribution network for immediate impact. We anticipate strong interest.”
The acquisition includes the full brand, and patented compound, a turnkey supply chain, existing sales, and committed transition support from co-founders Dr. Rosalynn Nazarian, a board-certified dermatopathologist, and Madeline Rodriguez.
Parties interested in exploring this acquisition opportunity are invited to contact GTT Group’s Managing Director Tyler McKinley at tmckinley@gttgrp.com for further details and a comprehensive offering review. All inquiries are kept strictly confidential.
About GTT Group
Global Technology Transfer Group, Inc. (www.gttgrp.com) is a market leader and pioneer in strategic intellectual property development, patent analysis, patent transaction (divestiture & acquisition), and patent enterprise value services and is the first mover in patent equity venture capital investing via its affiliated venture capital fund, Ideaship (www.ideashipfund.com). GTT Group’s patent asset house leverages core competencies in patent analysis, valuation, and market knowledge to deliver unparalleled results.The company’s corporate headquarters are in Portland, Oregon.
